Breaking News, Collaborations & Alliances

CBT, Bossan Enter Clinical Collaboration

The license agreement will allow companies to develop their respective assets in combination with each other

CBT Pharmaceuticals (CBT) and Zhejiang Bossan Pharmaceutical Co., Ltd (Bossan) have entered into a clinical collaboration and license agreement to develop their respective assets in combination with each other.    The license agreement grants CBT exclusive, worldwide rights outside of Greater China to develop and commercialize ES-072, Bossan’s novel epidermal growth factor receptor (EGFR) inhibitor, in combination with CBT’s proprietary c-Met inhibitor (CBT-101) and anti-PD1 antibody (CB...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters